Serum Inflammatory Markers and Integrity of the Superior Longitudinal Fasciculus and the Inferior Longitudinal Fasciculus in Schizophrenia, from Prodromal Stages to Chronic Psychosis-A Cross-Sectional Study.
UHR
cytokines
diffusion tensor imaging
first episode psychosis
inferior longitudinal fasciculus
inflammation
inflammatory markers
schizophrenia
superior longitudinal fasciculus
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
15 Jan 2023
15 Jan 2023
Historique:
received:
13
12
2022
revised:
29
12
2022
accepted:
12
01
2023
entrez:
21
1
2023
pubmed:
22
1
2023
medline:
22
1
2023
Statut:
epublish
Résumé
Chronic subclinical inflammation is believed to be an important factor in the pathogenesis of schizophrenia. Meta-analyses confirm the presence of increased levels of peripheral inflammatory markers (IM) in schizophrenia and its prodromal stages. Peripheral cytokines may affect the brain microstructure through chronic activation of microglia. Disruptions in the integrity of the superior longitudinal fasciculus (SLF) and inferior longitudinal fasciculus (ILF) are commonly seen in patients with schizophrenia spectrum disorders. We therefore attempted to verify in a cross-sectional study whether there is a correlation between levels of peripheral IM and the integrity of these brain regions in healthy controls, from prodromal states and first episode psychosis to long-term schizophrenia. The integrity of white matter was measured using diffusion tensor imaging. Despite a broad analysis of six IM (CRP, IL-6, IL-8, IL-10, TNF-α, and IFN-γ), we did not find any correlations with the integrity of the SLF or ILF in any of the analyzed groups (after correction for multiple comparisons). In conclusion, our study does not support the existence of a link between disrupted levels of peripheral IM and reduced integrity of ILF and SLF in schizophrenia spectrum disorders. However, prospective studies are needed to verify this over a long period of time.
Identifiants
pubmed: 36675612
pii: jcm12020683
doi: 10.3390/jcm12020683
pmc: PMC9866306
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : National Science Center
ID : 2019/03/X/NZ5/00719
Organisme : Ministry of Science and Higher Education
ID : 002/RID/2018/2019
Organisme : Pomeranian Medical University
ID : FSN-246-05/2017
Organisme : Pomeranian Medical University
ID : FSN-312-03/19
Références
Schizophr Bull. 2003;29(4):703-15
pubmed: 14989408
J Clin Med. 2021 Jun 06;10(11):
pubmed: 34204171
Brain Imaging Behav. 2020 Dec;14(6):2817-2830
pubmed: 31468374
Ann Intern Med. 2015 Aug 18;163(4):326
pubmed: 26280429
Prog Neuropsychopharmacol Biol Psychiatry. 2020 Aug 30;102:109955
pubmed: 32360815
Schizophr Res. 2015 Jan;161(1):119-25
pubmed: 25449712
J Med Virol. 2021 Jun;93(6):3915-3924
pubmed: 33155686
J Clin Med. 2021 May 21;10(11):
pubmed: 34063845
J Psychiatr Res. 2019 Aug;115:113-120
pubmed: 31128501
Psychol Med. 2019 Sep;49(12):1971-1979
pubmed: 31284882
Prog Neuropsychopharmacol Biol Psychiatry. 2014 Jan 3;48:277-86
pubmed: 23123365
J Neurosurg Sci. 2021 Dec;65(6):560-565
pubmed: 33940781
J Clin Psychiatry. 1998;59 Suppl 20:22-33;quiz 34-57
pubmed: 9881538
Psychiatry Investig. 2019 Mar;16(3):177-184
pubmed: 30836740
Clin Schizophr Relat Psychoses. 2014 Jan;7(4):223-30
pubmed: 23428789
Brain Sci. 2022 Mar 07;12(3):
pubmed: 35326310
Brain Behav Immun. 2018 May;70:315-324
pubmed: 29548996
Schizophr Res. 2018 Jul;197:19-33
pubmed: 29239785
Biochemistry (Mosc). 2017 Mar;82(3):264-274
pubmed: 28320267
J Clin Med. 2022 Oct 27;11(21):
pubmed: 36362580
Front Psychiatry. 2021 Mar 05;12:536257
pubmed: 33746786
Psychiatry Res Neuroimaging. 2017 Dec 30;270:8-21
pubmed: 28988022
J Affect Disord. 2016 Sep 15;202:1-9
pubmed: 27253210
Biol Psychiatry. 2011 Oct 1;70(7):663-71
pubmed: 21641581
Schizophr Bull. 1987;13(2):261-76
pubmed: 3616518
Neuroimage. 2010 Aug 1;52(1):1-8
pubmed: 20399275
Schizophr Res. 2020 Sep;223:158-165
pubmed: 32684357
Mol Psychiatry. 2018 May;23(5):1261-1269
pubmed: 29038599
PLoS One. 2014 Sep 04;9(9):e106521
pubmed: 25188448
J Neuroimaging. 2014 Mar-Apr;24(2):101-10
pubmed: 23317110
Pharmacol Rep. 2021 Feb;73(1):43-56
pubmed: 33125677
Front Neurosci. 2019 Feb 07;13:52
pubmed: 30792621
Mol Med Rep. 2017 Jul;16(1):603-608
pubmed: 28586011
J Psychiatr Res. 1998 May-Aug;32(3-4):143-50
pubmed: 9793867
Schizophr Res. 2018 Feb;192:16-29
pubmed: 28416092
Neurology. 2010 Mar 30;74(13):1022-9
pubmed: 20350977
Schizophr Bull. 1996;22(2):283-303
pubmed: 8782287
Psychiatr Pol. 2019 Jun 30;53(3):561-575
pubmed: 31522197
Neurochem Res. 2017 Sep;42(9):2625-2638
pubmed: 28540600
Psychoneuroendocrinology. 2021 May;127:105200
pubmed: 33740587
Riv Psichiatr. 2017 Mar-Apr;52(2):49-66
pubmed: 28492575
Prog Neuropsychopharmacol Biol Psychiatry. 2013 Aug 1;45:100-6
pubmed: 23648972
Prog Neuropsychopharmacol Biol Psychiatry. 2022 Jun 8;116:110510
pubmed: 35063597
J Clin Med. 2021 Jul 17;10(14):
pubmed: 34300325
Hum Brain Mapp. 2019 Oct 1;40(14):4180-4191
pubmed: 31187567
J Clin Med. 2021 Jun 04;10(11):
pubmed: 34199832
Neurosci Lett. 2009 Feb 27;451(3):232-6
pubmed: 19152829
Psychopharmacology (Berl). 2016 May;233(9):1559-73
pubmed: 26037944
J Clin Med. 2021 Aug 27;10(17):
pubmed: 34501305
Front Psychiatry. 2019 Dec 06;10:892
pubmed: 31908647
Brain Behav Immun. 2017 Feb;60:1-12
pubmed: 26995317
Psychosomatics. 1995 May-Jun;36(3):267-75
pubmed: 7638314
Schizophr Res. 2020 Dec;226:5-12
pubmed: 30967316